Spain Mammography - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The spain mammography market size is projected to be USD 67.47 million in 2025, USD 72.94 million in 2026, and reach USD 107.78 million by 2031, growing at a CAGR of 8.12% from 2026 to 2031. This report is Segmented by Product Type (Digital Systems, Breast Tomosynthesis (3-D), and More), End User (Hospitals, Diagnostic Centers, Specialty Clinics, Mobile Screening Units, Breast Imaging Centres), Technology (2-D Mammography, 3-D/DBT, AI-Assisted CAD, Contrast-Enhanced Digital Mammography), and Geography. Market Forecasts are Provided in Terms of Value (USD).

Spain Mammography Market Trends and Insights

Growing Breast-Cancer Incidence in Women 40-69

In 2024, Spain reported 36,395 new breast cancer diagnoses, making it the country's most prevalent malignancy. Catalonia experienced a 16% increase in cases over the past decade. The majority of diagnoses occur among women aged 50-69, aligning with the demographic targeted for biennial screening. Even slight increases in participation can drive system utilization rates beyond 85%. Advocacy efforts are pushing to expand screening age eligibility to 45-74, which could result in an additional 1.5 million screenings annually and require 20-25 more units to maintain wait times under 30 days. Awareness campaigns in October led to a 12% rise in self-referrals in 2024, further straining traditional analog platforms. These factors collectively highlight the growing demand for advanced digital systems.

Expansion of Biennial National Screening

All 17 autonomous communities in Spain invite women aged 50-69 to biennial screenings, but participation rates dropped from 83% in 2017 to 74% in 2020, primarily due to COVID-19-related disruptions. Five regions have extended invitations to women aged 45-49 and 70-74, providing valuable insights for an upcoming EU guideline revision. Real-time tracking by the national Cancer Surveillance System reveals disparities, with foreign-born women and rural residents participating at lower rates. Mobile units are being deployed to address these gaps. For instance, Galicia's mobile fleet increased coverage in towns with fewer than 5,000 residents from 68% to 79% within a year. Similarly, Andalusia's program screened 42,000 women in 2024, reflecting a 15% annual growth.

Radiologist Shortage Delaying AI Validation & Deployment

Prospective AI trials require extensive ground-truth labeling, but Spain's below-average radiologist density poses a significant challenge to this process. Kheiron's Mia algorithm demonstrated a 13% improvement in detection rates and a 25% reduction in interval cancers across three Catalan hospitals. However, broader implementation is contingent on the availability of local validation data. Additionally, the eHealth Network now requires BI-RADS-compliant metadata for cross-border data exchange, necessitating IT system upgrades in hospitals before large-scale AI pilot projects can proceed.

Other drivers and restraints analyzed in the detailed report include:

• Regional Tenders Accelerating 3-D Tomosynthesis Roll-Out
• Shift to Personalized, Risk-Based Screening Models
• Reimbursement Gaps for Tomosynthesis Outside Public Programs

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, Spain's digital mammography market was valued at USD 57.34%, with a projected CAGR of 11.50% through 2031. The AMAT-I fund initiatives are driving the adoption of low-dose, energy-efficient detectors, accelerating the shift from analog systems. Long-term service agreements, such as GE HealthCare's recent contract in Huesca, are increasing switching costs and strengthening the position of established players. While tomosynthesis platforms command a 30-40% price premium, procurement decisions are justified by sensitivity improvements, such as a 15% gain reported by leading hospitals. However, contrast-enhanced digital mammography adoption remains limited due to reimbursement challenges, restricting its use to private networks catering to self-pay patients.

Rising R&D efforts are focusing on detector materials that reduce the average glandular dose by up to 30%, aligning with sustainability goals in healthcare. Vendors are also integrating AI-triage software to streamline workflows by prioritizing high-suspicion cases, enabling radiologists to focus on complex analyses. The market increasingly favors cloud-ready platforms, driven by regional health IT projects requiring Vendor-Neutral Archives to manage tomosynthesis datasets without on-premise servers. With federal funding tied to energy efficiency and cybersecurity compliance, digital systems are expected to continue outpacing analog replacements.

Complete Report Scope:

• By Product Type
  • Digital Systems
  • Breast Tomosynthesis (3-D)
  • Analog Systems
  • Contrast-Enhanced Digital Mammography
• By End User
  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Mobile Screening Units
  • Breast Imaging Centres
• By Technology
  • 2-D Mammography
  • 3-D / DBT
  • AI-Assisted CAD
  • Contrast-Enhanced Digital Mammography

List of Companies Covered in this Report:

• Agfa-Gevaert
• Analogic
• Canon Inc. (Canon Medical Systems)
• Carestream Health
• CMR Naviscan Corp.
• ESAOTE SpA
• FUJIFILM
• GE Healthcare
• General Medical Merate
• Hologic
• iCAD Inc.
• IMS Giotto SpA
• Incepto Medical Iberia
• Koninklijke Philips
• Kubtec Medical Imaging
• Metaltronica
• Miwendo Solutions
• Palex Medical
• Planmed
• Samsung Medison Co. Ltd.
• Sectra
• Shimadzu
• Siemens Healthineers

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support